Amylyx Pharmaceuticals (AMLX) Net Cash Flow (2021 - 2026)

Amylyx Pharmaceuticals' Net Cash Flow history runs 6 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 114.57% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $168.1 million (up 252.96% YoY), while the FY2025 annual figure was $147.7 million, up 261.19% from the prior year.
• Net Cash Flow was $2.6 million for Q1 2026 at Amylyx Pharmaceuticals, up from $1.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $166.5 million in Q3 2025 to a low of -$112.4 million in Q3 2023.
• Historically, Net Cash Flow has averaged $10.5 million across 5 years, with a median of $1.4 million in 2025.
• Biggest YoY gain for Net Cash Flow was 6325.65% in 2025; the steepest drop was 3965.73% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$45.7 million in 2022, then surged by 175.92% to $34.7 million in 2023, then plunged by 82.48% to $6.1 million in 2024, then tumbled by 77.69% to $1.4 million in 2025, then soared by 91.38% to $2.6 million in 2026.
• The last three Net Cash Flow figures came in at $2.6 million (Q1 2026), $1.4 million (Q4 2025), and $166.5 million (Q3 2025), per Business Quant data.